Please try another search
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Margitta Seeck | - | - | Member of Scientific Advisory Board |
Annamaria Vezzani | - | - | Member of Scientific Advisory Board |
Lars Thunberg | 58 | 2006 | Deputy Board Member |
Andrew S.C. Rice | - | 2023 | Member of Scientific Advisory Board |
David Bennett | - | 2023 | Member of Scientific Advisory Board |
Lars Arendt-Nielsen | - | 2023 | Member of Scientific Advisory Board |
Marcus Isaksson | - | 2024 | Director |
Luca Di Stefano | 46 | 2024 | Chairman of the Board |
Sten Linnarsson | - | 2024 | Member of the Scientific Advisory Board |
Jakob Færch Bendtsen | 46 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review